Boehringer Ingelheim To Evaluate Combination Of Dll3‑Targeting T‑Cell Engager Plus Pd‑L1/Vegf‑A Bispecific Antibody In Small Cell Lung Cancer
April 9 (Reuters) - BioNTech SE 22UAy.DE:
BOEHRINGER INGELHEIM: TO EVALUATE COMBINATION OF DLL3‑TARGETING T‑CELL ENGAGER PLUS PD‑L1/VEGF‑A BISPECIFIC ANTIBODY IN SMALL CELL LUNG CANCER
BOEHRINGER INGELHEIM: BIONTECH WILL SUPPLY PUMITAMIG AND CO WILL BE REGULATORY SPONSOR OF PHASE IB/II STUDY
BOEHRINGER INGELHEIM: BIONTECH AND CO RETAIN FULL RIGHTS TO THEIR RESPECTIVE ASSETS, AND AGREEMENT IS MUTUALLY NON-EXCLUSIVE
BOEHRINGER INGELHEIM: TRIAL WILL BEGIN DOSING PATIENTS IN SECOND HALF OF 2026
Further company coverage: [22UAy.DE]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Brent Spot $190 Warning: WTI Flips Global Benchmark in Rare Price Inversion as Geopolitical Tensions Flare

Intel Stock's Rare Surge: What’s Driving the Rally and Is It Worth Buying in 2026?

Tradingkey








